Pediatric Intensive Care Unit, Department of Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China.
J Dermatol. 2019 Oct;46(10):898-901. doi: 10.1111/1346-8138.15031. Epub 2019 Aug 2.
Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA) are rare infiltrative vascular tumors. Currently, no standard treatment regimens exist for KHE/TA. The purpose of our study was to evaluate the efficacy and safety of topical application of tacrolimus for superficial KHE/TA. We examined six patients with superficial KHE/TA. All patients were treated with tacrolimus 0.1% ointment twice daily for at least 12 months. The response rate was 100%, including three nearly complete remissions. Only one patient experienced local pruritus during treatment. The data constituted an intriguing rationale for clinical trials of topical tacrolimus in the treatment of superficial KHE/TA.
卡波西样血管内皮细胞瘤(KHE)和丛状血管瘤(TA)是罕见的浸润性血管肿瘤。目前,尚无针对 KHE/TA 的标准治疗方案。我们的研究目的是评估他克莫司局部应用于浅表性 KHE/TA 的疗效和安全性。我们检查了 6 例浅表性 KHE/TA 患者。所有患者均使用他克莫司 0.1%软膏,每日两次,至少治疗 12 个月。反应率为 100%,包括 3 例几乎完全缓解。只有 1 名患者在治疗期间出现局部瘙痒。这些数据为他克莫司局部治疗浅表性 KHE/TA 的临床试验提供了有趣的依据。